Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$113.20 USD
-2.90 (-2.50%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $108.00 -5.20 (-4.59%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Jazz Pharmaceuticals PLC has a market cap of $7.03B, which represents its share price of $116.10 multiplied by its outstanding shares number of 60.51M. As a mid-cap company, JAZZ's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
JAZZ 113.20 -2.90(-2.50%)
Will JAZZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Other News for JAZZ
Q2 2025 Jazz Pharmaceuticals PLC Earnings Call Transcript
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals (JAZZ) Adjusts FY25 Revenue Outlook
Earnings Scheduled For August 5, 2025
Jazz Pharmaceuticals Q2 2025 Earnings: Revenue Hits $1.05 Billion, EPS Falls Short at -$11.74